In a groundbreaking study led by researchers at the Karolinska Institutet and collaborators across Europe and Asia, a new chapter in cancer immunotherapy is being written—one where adaptive Natural Killer (aNK) cells may offer long-lasting, tumor-specific immune memory against one of the deadliest gynecological cancers: high-grade serous ovarian cancer (HGSOC).
Natural Killers with a Memory
Traditionally, Natural Killer (NK) cells have been considered blunt instruments of the immune system—quick to act, but lacking precision and memory. However, this study overturns that view, focusing on adaptive NK cells—a distinct subset that not only remembers its targets but becomes more effective with each encounter.
Researchers discovered that aNK cells can recognize specific antigens from ovarian tumor cells, infiltrate the tumor microenvironment, and mount strong cytotoxic responses. Unlike conventional NK (cNK) cells, which respond broadly but without specificity, aNK cells showed an ability to recall past tumor interactions—mirroring how memory T cells function in viral immunity.
The Science Behind the Memory
The team employed a range of advanced methods—single-cell RNA sequencing, ex vivo tumor models, and multiplex tissue imaging—to track how aNK cells operate. Notably, aNK cells formed close relationships with dendritic cells (DCs) via the HLA-E/NKG2C pathway and chemokine receptor CXCR2, which helped establish immune memory and improve tumor targeting.
In a key finding, aNK cells demonstrated superior killing of autologous (patient-derived) ovarian cancer cells when compared to cNK cells and even T cells. These tumor-targeting effects were observed weeks after priming, indicating true immunological memory.
Why Ovarian Cancer?
Ovarian cancer is often diagnosed late and is notoriously difficult to treat due to its immunosuppressive tumor environment and diffuse growth throughout the abdomen. The researchers selected HGSOC as their model because its moderate immune infiltration provided a suitable landscape to evaluate whether aNK cells could thrive—and they did.
aNK cells not only persisted but also outperformed other immune cells in infiltrating the tumor nest, resisting suppression, and executing targeted cell death.
Implications for Future Immunotherapy
This study paves the way for aNK-cell-based cancer immunotherapies that go beyond the short-lived responses seen with traditional treatments. By leveraging aNK cells’ memory capabilities and tumor specificity, researchers envision new therapies that could be more effective against solid tumors.
Moreover, the role of dendritic cells in priming aNK cells suggests potential synergies with DC-based vaccines and strategies for engineering memory-enabled NK cells from induced pluripotent stem cells (iPSCs).
Cosmael ThinkLab Commentary
This research represents a significant shift in our understanding of the innate immune system’s capacity for memory. It blurs the classical boundary between adaptive and innate immunity—revealing that NK cells can evolve from “natural killers” into intelligent assassins with a hit list.
From a clinical perspective, this opens exciting possibilities. Combining aNK cells with precision antigen loading, targeted cytokine cocktails, or even DC vaccines could enable long-term control over aggressive cancers like HGSOC. The challenge now lies in translating these insights into scalable, cost-effective therapies—and ensuring they reach the patients who need them most.
Original Research Source:
Sun Y, Furones AR, Gultekin O, Khare S, Neo SY, Shi W, Moyano-Galceran L, et al. “Adaptive NK Cells Exhibit Tumor-Specific Immune Memory and Cytotoxicity in Ovarian Cancer.” Cancer Immunology Research, 2025.
DOI: 10.1158/2326-6066.CIR-24-0852